Company / Revenue
Inhibikase Therapeutics, Inc. Revenue History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$260.5K
FY2024
5-year range
$123.4K / $3.1M
FY2021-FY2024
Trend
+111.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $3M to $260,501 over the past 2 years.
Based on SEC 10-K filings.
$260,501 in FY2024 with a 3-year CAGR of -28.0%.
Declined from $3M to $260,501 over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -28.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -28.0%, indicating a declining trend.
- In FY2024, revenue increased 111.0% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $260.5K | +111.0% |
| FY2023 | $123.4K | -96.0% |
| FY2022 | $3.1M | +343.9% |
| FY2021 | $698.5K | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026